Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Feed Symbols: ACRS

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Earnings

Aclaris Therapeutics Earnings Perspective: Return On Capital Employed

By Benzinga Insights
May 22, 10:48 AM
Benzinga Pro data, Aclaris Therapeutics (NASDAQ:ACRS) reported Q1 sales of $2.53 million. Earnings fell to a loss of…

ACRS

Read More
13 minute read
  • Earnings

Earnings Scheduled For May 8, 2023

By Benzinga Insights
May 8, 9:03 AM
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.

ACAD

Read More
1 minute read
  • Earnings

Aclaris Therapeutics’s Earnings Outlook

By Benzinga Insights
May 5, 11:03 AM
Aclaris Therapeutics (NASDAQ:ACRS) is set to give its latest quarterly earnings report on Monday, 2023-05-08. Here’s what investors…

ACRS

Read More
1 minute read
  • Biotech
  • ETFs
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Sector ETFs
  • Small Cap

Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason

By Vandana Singh
March 7, 8:34 PM
The Health Care Select Sector SPDR Fund (NYSE:XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies…

ABBV

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

BTIG Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $29

By Benzinga Newsdesk
March 7, 7:54 AM
BTIG analyst Julian Harrison maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $32 to $29.

ACRS

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $43

By Benzinga Newsdesk
March 7, 7:15 AM
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $50 to $43.

ACRS

Read More
3 minute read
  • Commodities
  • Earnings
  • Eurozone
  • Global
  • Intraday Update
  • Markets
  • News
  • Penny Stocks
  • Small Cap

Nasdaq Rises 50 Points; Ciena Earnings Top Expectations

By Lisa Levin
March 6, 3:24 PM
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P 500 also rose, gaining, 0.35% to 4,059.80.

ACRS

Read More
3 minute read
  • Commodities
  • Earnings
  • Eurozone
  • Global
  • Intraday Update
  • Markets
  • News
  • Penny Stocks
  • Small Cap

Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher

By Lisa Levin
March 6, 1:25 PM
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500 also rose, gaining, 0.69% to 4,073.40.

ACRS

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics, Maintains $38 Price Target

By Benzinga Newsdesk
February 7, 8:42 AM
Cantor Fitzgerald analyst Louise Chen reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and maintains $38 price target.

ACRS

Read More
15 minute read
  • Analyst Ratings
  • Downgrades
  • Initiation
  • Intraday Update
  • Upgrades

Benzinga’s Top Ratings Upgrades, Downgrades For December 1, 2022

By Benzinga Insights
December 1, 11:01 AM
Upgrades Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55…

ACRS

Posts navigation

1 2 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service